In the post-market session on Thursday, shares of Inozyme Pharma, Inc. (NASDAQ: INZY) exhibited an upward trajectory. Notably, the stock experienced a notable ascent of 7.45%, reaching a value of $3.46 during the extended trading period. In the preceding regular session, the performance of INZY stock was relatively stable, registering a modest increase of 0.62% and concluding at $3.22. The positive momentum in INZY stock was spurred by the active involvement of its leadership in a significant event.

The Chief Executive Officer and Chairman of INZY, Dr. Douglas A. Treco, participated at The Jefferies London Healthcare Conference held recently. Additionally, the executive is slated to participate in The Piper Sandler 35th Annual Healthcare Conference, engaging in a fireside chat scheduled for Thursday, November 30, from 12:00 to 12:25 pm ET.

Furthermore, Inozyme Pharma recently issued a comprehensive business update. The company reported the initiation of patient recruitment for the pivotal ENERGY-3 trial of INZ-701, focusing on pediatric patients with ENPP1 Deficiency. INZY is on course to unveil topline data in mid-2025. Encouraging outcomes from the phase 1/2 clinical trial of INZ-701 in adults with ENPP1 Deficiency were also disclosed.

The ongoing trial demonstrated positive interim results in safety, pharmacokinetics (PK), pharmacodynamics (PD), and exploratory efficacy data. Notably, exploratory data indicated clinical benefits for ENPP1 Deficiency, encompassing improvements in key biomarkers, patient-reported outcomes (PROs), and functional outcomes. The Phase 2 portion of the trial is actively dosing, with the company anticipating reporting topline clinical data from the first three cohorts through 48 weeks in the first quarter of 2024.

Similarly, the phase 1/2 clinical trial of INZ-701 in adults with ABCC6 Deficiency yielded positive interim results in safety, PK, PD, and exploratory efficacy data. All three dose cohorts exhibited improvements in the Global Impression of Change (GIC), a PRO.

The company is on track to disclose topline clinical data through 48 weeks in the first quarter of 2024. Inozyme also unveiled plans for an oral presentation at the American Society for Nephrology (ASN) Kidney Week 2023 and intends to present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting.